Therefore, we retrospectively evaluated patient characteristics, treatment status, and the efficacy and safety of osimertinib treatment in clinical practice through a multicenter evaluation of patients who received osimertinib for previously EGFR‐TKI‐treated advanced/recurrent T790M‐positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.